Lexicon Pharmaceuticals reported a strong start to 2025, with total revenues increasing to $1.3 million from $1.1 million in the prior year period. The company significantly reduced its net loss to $25.3 million from $48.4 million year-over-year, reflecting lower operating expenses due to strategic repositioning. Key achievements include an exclusive licensing agreement for LX9851 with Novo Nordisk and positive Phase 2b results for pilavapadin.

Lexicon Pharmaceuticals reported a significant revenue increase in Q4 2024, primarily driven by a $25 million upfront payment from the Viatris INPEFA licensing agreement. Despite higher R&D expenses, net loss narrowed due to improved revenue generation.

Lexicon Pharmaceuticals reported a net loss of $48.4 million, or $0.20 per share, for the first quarter of 2024. Revenues were $1.1 million, primarily from INPEFA. The company is advancing its pipeline, including a planned NDA resubmission for ZYNQUISTA and initiation of a Phase 3 study for sotagliflozin in HCM. They had $355.6 million in cash and investments as of March 31, 2024.

Lexicon Pharmaceuticals reported Q3 2023 financial results, featuring the commercial launch of INPEFA, which saw increasing prescription demand, and the progression of LX9211 into late-stage development for diabetic peripheral neuropathic pain. The company is seeing important formulary wins, with some of the more notable becoming effective on November 1st. Revenue for the quarter was $0.2 million, and the net loss was $50.5 million, or $0.21 per share.

Lexicon Pharmaceuticals reported a net loss of $44.9 million, or $0.22 per share, for the second quarter of 2023. The company received FDA approval for INPEFA and commercially launched it in the U.S. LX9211 is moving into late-stage development for diabetic peripheral neuropathic pain.

Lexicon Pharmaceuticals reported a net loss of $31.9 million for the first quarter of 2023, compared to a net loss of $23.5 million for the corresponding period in 2022. As of March 31, 2023, Lexicon had $105.9 million in cash and investments.

Lexicon Pharmaceuticals reported a net loss of $30.5 million for the fourth quarter of 2022, compared to a net loss of $25.6 million for the same period in 2021. As of December 31, 2022, Lexicon had $138.4 million in cash and investments.

Lexicon Pharmaceuticals reported a net loss of $23.4 million for Q3 2022, with R&D expenses decreasing and SG&A expenses increasing compared to the same period in 2021. The NDA for sotagliflozin remains on track for a May 2023 PDUFA date.

Lexicon Pharmaceuticals reported its Q2 2022 financial results, highlighted by the acceptance of the sotagliflozin New Drug Application (NDA) for heart failure by the FDA and positive top-line results from its Phase 2 RELIEF-DPN-1 study of LX9211 in painful diabetic neuropathy.

Lexicon Pharmaceuticals reported a net loss of $23.5 million, or $0.16 per share, for the first quarter of 2022. The company is preparing to resubmit its New Drug Application for sotagliflozin and expects top-line results for the Phase 2 study of LX9211 in diabetic peripheral neuropathic pain by the end of this quarter.

Lexicon Pharmaceuticals reported negligible revenues for the fourth quarter. R&D expenses increased, while SG&A expenses also increased. The net loss for the quarter was $25.6 million, or $0.17 per share. As of December 31, 2021, Lexicon had $86.7 million in cash and investments.

Lexicon Pharmaceuticals reported its third quarter 2021 financial results, with revenues being negligible compared to the previous year due to the sale of XERMELO®. Research and development expenses decreased, as did selling, general, and administrative expenses. The net loss for the quarter was $23.1 million, compared to a net income of $82.6 million in the same period of 2020, which included a gain from the sale of XERMELO®.

Lexicon Pharmaceuticals reported its Q2 2021 financial results, with revenues decreasing to $0.2 million from $9.2 million in the corresponding period of 2020, primarily due to the sale of XERMELO. Research and development expenses also decreased to $10.3 million from $57.3 million. Net loss for the quarter was $18.1 million, or $0.13 per share.

Lexicon Pharmaceuticals reported negligible revenues for the first quarter of 2021, primarily due to the absence of product revenues following the sale of XERMELO in Q3 2020. Net loss for the quarter was $21.0 million, or $0.15 per share, compared to a net loss of $66.6 million, or $0.63 per share, for the corresponding period in 2020. The company had $141.4 million in cash and investments as of March 31, 2021.

Lexicon Pharmaceuticals reported a decrease in revenues for the fourth quarter of 2020, primarily due to the sale of XERMELO. The company is focusing on advancing its research and development pipeline, with key steps taken to advance LX9211 and sotagliflozin.

Lexicon Pharmaceuticals reported a decrease in revenues to $6.6 million, primarily due to the termination of the alliance with Sanofi in the previous year. Net income was $82.6 million, driven by a gain on the sale of XERMELO. The company is focusing on the advancement of LX9211 and has commenced a Phase 2 study in diabetic peripheral neuropathic pain.

Lexicon Pharmaceuticals reported a decrease in revenues to $9.2 million, primarily due to a decrease of bulk tablet sales of XERMELO to Ipsen and collaborative revenues, partially offset by an increase in U.S. net product revenue. Net loss was $69.1 million, or $0.65 per share, as compared to a net loss of $23.0 million, or $0.22 per share, in the corresponding period in 2019. XERMELO U.S. net sales were $9.0 million, up 21% from the prior year quarter.

Lexicon Pharmaceuticals reported a decrease in revenues to $8.0 million, driven by lower collaborative revenues, although XERMELO net sales increased by 17%. R&D expenses significantly increased due to sotagliflozin development costs. The net loss was $66.6 million, or $0.63 per share, compared to a net loss of $21.8 million, or $0.21 per share, in the prior year.

Lexicon Pharmaceuticals reported a decrease in revenues for the fourth quarter to $8.7 million from $17.1 million for the corresponding period in 2018, primarily due to lower revenues recognized under collaboration and license agreements. Net loss for the fourth quarter was $51.1 million, or $0.48 per share, as compared to a net loss of $16.8 million, or $0.16 per share, in the corresponding period in 2018.